![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- World Health Organisation. Global Health Estimates 2010–2011. Geneva, Switzerland 2014 http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/. Accessed 05/06/14
- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr. Accessed 05/06/2014
- Nurgaziyev K Sh, Seytkazina GD, Baypeisov DM, et al. 2012 Indicators of oncological service of the Republic of Kazakhstan for 2012. Ministry of Health, Kazakhstan, 2012
- Cardoso F, Harbeck N, Fallowfield L, et al. European Society for Medical Oncology Clinical Practice Guidelines. Annals of Oncology 2012;23(7 Suppl):vii7-173
- National Institute for Health and Clinical Excellence. Advanced breast cancer: diagnosis and treatment. Full guideline. CG81. London: NICE, 2009
- National Institute for Health and Clinical Excellence. Guidance on the use of trastuzumab for the treatment of advanced breast cancer. TA34. London: NICE, 2002
- Boulay A, Zumstein-Mecker S, Stephen C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-61
- Piccart M, Noguchi S, Pritchard KI, et al. ASCO Annual Meeting, June 1-5 2012, Chicago, IL
- Baselga J, Campare M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEJM 2012;336:520-9
- Beaver J, Park B. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive breast cancer. Future Oncol 2012;8:651-7
- DataMonitor. Epidemiology: breast cancer. In: McGuill M, ed. Epidemiology series. Datamonitor, London, UK, 2010
- European Medicines Agency. Assessment Report 2012. London, UK 2012. Afinitor. EMEA/H/C/001038/II/0020
- Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-201
- Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. Sheffield, UK: University of Sheffield, 2011
- Sacco J, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 2010;5:e8933
- Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24
- Order of Chairman of the Board of ‘SK-Pharmaceuticals’ LLP No. 06/62 as of June 10, 2013
- Minister of Health. Attachment 1, 2 to Minister of Healthcare of the Republic of Kazakhstan Order No. 444 as of July 1, 2011. Kazakhstan: Ministry of Health, 2013